Astellas Reports 20.7% Year-over-Year Revenue Growth in Greater China for FY2022

On May 8, Astellas Pharma Group announced its global financial results for the fiscal year 2022 ended March 31 through its official WeChat account. The total sales revenue for the fiscal year 2022 was 1,518.6 billion yen, representing a year-on-year increase of 17.2%; core profit was 286.9 billion yen, also increasing by 17.2% year-on-year. Among this, revenue from Greater China reached 80 billion yen, marking a year-on-year growth of 20.7%.